JP Morgan Call 94 CF 21.06.2024/ DE000JK69U50 /
31.05.2024 10:56:41 | Diff.0.000 | Geld22:00:39 | Brief22:00:39 | Basiswert | Basispreis | Fälligkeit | Optionsart |
---|---|---|---|---|---|---|---|
0.004EUR | 0.00% | - Geld Vol: - |
- Brief Vol: - |
CF Industries Holdin... | 94.00 USD | 21.06.2024 | Call |
GlobeNewswire
19:02
Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily Pret...
GlobeNewswire
16:00
SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstr...
GlobeNewswire
16:00
Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Gli...
GlobeNewswire
16:00
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates M...
GlobeNewswire
15:14
Flash News: OKX Announces Position Tier Adjustments for TURBO/USDT Perpetual Futures Listing
GlobeNewswire
15:00
ClearPoint Neuro Announces Full Market Release of SmartFrame OR™ and ClearPoint PRISM® 3T Laser Ther...
GlobeNewswire
15:00
Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monothera...
GlobeNewswire
14:15
FSLY INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Fastly, Inc. Investors with ...
GlobeNewswire
14:15
Y-mAbs Announces Publication of Preclinical GD2-SADA Data at 2024 ASCO Annual Meeting
GlobeNewswire
14:05
Y-mAbs Announces New Interim Analysis of Phase 2 Data for Naxitamab at 2024 ASCO Annual Meeting
GlobeNewswire
14:00
Kaskela Law LLC Announces Shareholder Investigation of WideOpenWest, Inc. (NYSE: WOW) and Encourages...
GlobeNewswire
14:00
Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonst...
GlobeNewswire
14:00
Molecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin)...
GlobeNewswire
14:00
OkayCoin CEO Releases Key Strategies to Maximize Investor Returns on Staking Platform
GlobeNewswire
14:00
Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at...
- Erste Seite
- Zurück
- 1
- 2
- 3
- 4
- Weiter
- Letzte Seite